Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

NOXXON Spiegelmer programs go to Aptarion
April 2017
SHARING OPTIONS:

BERLIN—January saw NOXXON Pharma N.V. ink an agreement with Aptarion biotech AG to license enabling technology, assign certain preclinical and technology research programs and transfer lab assets in exchange for cash, royalties and an equity stake in Aptarion. NOXXON has maintained exclusive rights to Spiegelmers—plasma-stable, nonimmunogenic, mirror-image (l-configured) aptamers—binding to the targets of its clinical-stage programs. Otherwise, the agreement allows both companies to use the Spiegelmer technology, and a cross-licensing provision provides for continued access to new enabling inventions to be used by both companies.
 
“This agreement is another step on the transition of NOXXON to a clinical-stage oncology company. With our focus on clinical development of our programs in oncology, we made the decision to spin-out the other assets, and this agreement with Aptarion is, we believe, the best opportunity to see them successfully developed,” commented Aram Mangasarian, CEO of NOXXON.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.